UPDATE: Morgan Stanley Reiterates Overweight Rating, Removes PT on Boston Scientific Corporation on Three Key Debates

In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on

, but removed the $15.00 price target. In the report, Morgan Stanley noted, “Key discussion topics at recent management meetings centered on three key debates: CRM (including S-ICD), Watchman, and margins. Fluid messaging may have raised uncertainty for some investors, but we believe the thesis remains on track.” Boston Scientific Corporation closed on Monday at $12.76.